Skip to search formSkip to main contentSkip to account menu

N 696

Known as: N-696 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
SummarySix weeks of treatment with carvedilol, N-696, celiprolol, dilevalol, acebutolol, urapidil, doxazosin and altiopril… 
1988
1988
To investigate the hemodynamic effects of tilisolol (N-696), a new β-blocking agent with vasodilating property, and doxazosin, a… 
1985
1985
To characterize the alpha 1-adrenoceptors in the dog aorta and the rat brain and to assess the antagonistic potencies of various… 
1985
1985
4-[3-(tert-Butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril hydrochloride (N-696) is a new beta-adrenoceptor blocking drug… 
1985
1985
Binding characteristics of the β-antagonists and agonists with the β-adrenoceptors were investigated in [3H] dihydroalprenolol… 
1984
1984
To characterize the pharmacological profile of a new beta-adrenoceptor blocker, 4-[3-(tert-butylamino)-2-hydroxypropoxy]-N… 
1984
1984
We evaluated antiarrhythmic effects of N-696 using canine digitalis ventricular arrhythmia models and electrophysiological… 
1983
1983
Summary We determined the minimum effective plasma concentrations of several antiarrhythmic agents against canine halothane… 
1983
1983
Effects of beta-blockers on the blood pressure (BP), urinary output (V) and excretion of Na% (UNaV) and K+ (UKV) were studied in…